CSTK - ETF AI Analysis
Top Page
Invesco Comstock Contrarian Equity ETF (CSTK)
CSTK, the Invesco Comstock Contrarian Equity ETF, earns a solid overall rating driven largely by strong, diversified holdings like Alphabet, Microsoft, Merck, and Elevance Health, which benefit from robust financial performance, growth in AI and healthcare, and generally positive momentum. The fund is somewhat held back by weaker names such as Philip Morris and CVS Health, where high leverage, bearish technical trends, and specific business challenges add risk. The main risk factor is its meaningful exposure to financials and healthcare companies, which can be sensitive to economic cycles, regulation, and sector-specific pressures.
CSTK vs. SPDR S&P 500 ETF (SPY)
- AUM
- 185.10M
- Region
- Global
- Expense Ratio
- 0.35%
- Beta
- 0.66
- Issuer
- Invesco
- Inception Date
- May 07, 2025
- Dividend Yield
- 1.79%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
CSTK Summary
The Invesco Comstock Contrarian Equity ETF (CSTK) is an actively managed fund that looks for undervalued companies, mainly in the U.S., rather than tracking a fixed index. It focuses on “value” stocks across many sectors, including financials, health care, technology, and energy. Well-known holdings include Microsoft and Alphabet (Google’s parent company), along with large banks and health care firms. Someone might invest in CSTK to seek long-term growth and income while spreading their money across many industries. A key risk is that these value stocks can still fall in price and move up and down with the overall stock market.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because CSTK is actively managed, with professionals picking undervalued stocks rather than simply tracking a market index.
What would affect this ETF?
CSTK could benefit if global economic growth improves and undervalued financial, health care, and technology companies recover, especially its major holdings like Alphabet, Microsoft, and large banks, as investors rotate into value stocks. On the downside, rising interest rates, weaker global growth, or tighter regulations on big tech, banks, energy, and health care firms could hurt the fund’s contrarian value positions and slow performance.
CSTK Top 10 Holdings
CSTK leans into a contrarian mix of Big Tech, health care, energy, and financials, with a clear tilt toward U.S. blue chips. Microsoft and Cisco are helping to power the fund, with steady-to-rising momentum tied to cloud and networking demand, while Merck and Elevance add a healthy dose of defensive strength from the medical side. Chevron has been a bright spot, riding firm energy markets. On the flip side, Alphabet is lagging and big banks like Bank of America and Wells Fargo are losing steam, creating a tug-of-war between value plays and tech resilience.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 GOOGL | Alphabet Class A | 3.17% | $5.89M | $3.41T | -0.58% | 85Outperform |
 MSFT | Microsoft | 3.43% | $6.37M | $3.88T | -0.73% | 79Outperform |
 CVX | Chevron | 3.13% | $5.81M | $465.33B | 53.41% | 71Outperform |
 CSCO | Cisco Systems | 2.92% | $5.42M | $411.45B | 43.34% | 77Outperform |
 WFC | Wells Fargo | 2.94% | $5.45M | $250.35B | -3.01% | 80Outperform |
 PM | Philip Morris | 2.90% | $5.39M | $325.43B | 43.24% | 61Neutral |
 BAC | Bank of America | 2.57% | $4.76M | $346.20B | -5.69% | 72Outperform |
 CVS | CVS Health | 2.50% | $4.64M | $115.43B | 17.68% | 64Neutral |
 ELV | Elevance Health | 2.42% | $4.50M | $90.76B | 30.48% | 76Outperform |
 MRK | Merck & Company | 2.36% | $4.38M | $368.89B | 73.30% | 80Outperform |
CSTK Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CSTK, the sentiment is Positive. The current price of 33.43 is above the 20-day moving average (MA) of 33.35, above the 50-day MA of 33.30, and above the 200-day MA of 31.71, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 51.73 is Neutral, neither overbought nor oversold. The STOCH value of 61.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CSTK.
CSTK Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| CSTK | $33.43 | $36.00(7.70% Upside) | $185.10M | 0.35% | 71Outperform |
 GMOI | $40.30 | $44.18(9.63% Upside) | $694.18M | 0.60% | 67Neutral |
 FPAG | $41.92 | $48.30(15.22% Upside) | $663.96M | 0.49% | 60Neutral |
 MFSV | $29.79 | $33.66(12.98% Upside) | $671.32M | 0.44% | 72Outperform |
 BINV | $44.39 | $52.54(18.37% Upside) | $540.27M | 0.70% | 58Neutral |
 COPY | $15.76 | $17.47(10.83% Upside) | $429.83M | 0.80% | 58Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CSTK | Invesco Comstock Contrarian Equity ETF | 33.43 | 6.15 | 22.56% | |
| GMOI | GMO International Value ETF | 40.30 | 9.45 | 30.62% | |
| FPAG | FPA Global Equity ETF | 41.92 | 6.22 | 17.43% | |
| MFSV | MFS Active Value ETF | 29.79 | 4.57 | 18.11% | |
| BINV | Brandes International ETF | 44.39 | 6.71 | 17.80% | |
| COPY | Tweedy Browne Insider + Value ETF Trust Units | 15.76 | 3.62 | 29.78% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.